GVp auditing Services

Our GVP Auditing Services

Good Pharmacovigilance Practice ensures that the safety of medicines is monitored throughout their lifecycle. Once a product is on the market, pharmacovigilance systems must detect, assess, understand, and prevent adverse effects. GVP audits verify that these systems are functioning correctly and that safety data is reliable. GxP Cellators provides GVP auditing services for marketing authorization holders, pharmacovigilance service providers, and companies with safety obligations. Our auditors understand the regulatory requirements and the practical realities of managing safety data at scale

Global Regulatory Frameworks for GVP

EMA

GVP Modules

FDA

Postmarketing

Health Canada

Vigilance

MHRA

Yellow Card

WHO

Drug Monitoring

ICH

Guidelines

Global Regulatory Frameworks for GVP

EMA GVP Modules

The European Medicines Agency publishes Good Pharmacovigilance Practice modules that set out requirements for pharmacovigilance systems in the EU. Module I covers Pharmacovigilance systems and their quality systems. Module II covers Pharmacovigilance system master file. Module V covers Risk management systems. Module VI covers Collection, management and submission of reports. Module VIII covers Post authorization safety studies. Module IX covers Signal management. Module XV covers Safety communication. Module XVI covers Risk minimization measures.

Summary of Key EMA GVP Modules:

FDA Pharmacovigilance Requirements

The FDA regulates pharmacovigilance through requirements for postmarketing reporting of adverse drug experiences. 21 CFR 314.80 covers postmarketing reporting of adverse drug experiences. 21 CFR 314.98 covers postmarketing reports for approved applications. 21 CFR 600.80 covers biological products. Safety reporting timelines require 15 days for serious unexpected events. Periodic safety reports are required at defined intervals.

Summary of Key FDA Pharmacovigilance Requirements:

Health Canada Pharmacovigilance Requirements

Health Canada regulates pharmacovigilance through the Food and Drug Regulations and the Canada Vigilance Program. The Food and Drug Regulations cover post market reporting. The Canada Vigilance Program covers adverse reaction reporting. Risk management plans are required for certain products.

Summary of Key Health Canada Pharmacovigilance Requirements:

MHRA Pharmacovigilance Requirements

The MHRA regulates pharmacovigilance in the United Kingdom through UK specific requirements. UK pharmacovigilance requirements post Brexit include the Yellow Card Scheme for adverse reaction reporting, risk management plans, and periodic safety update reports.

Summary of Key MHRA Pharmacovigilance Requirements:

WHO Pharmacovigilance Guidelines

The World Health Organization publishes pharmacovigilance guidelines that serve as an international reference. This includes the WHO Programme for International Drug Monitoring and guidelines on safety monitoring of medicinal products.

Summary of Key WHO Pharmacovigilance Guidelines:

ICH Guidelines

The International Council for Harmonisation publishes guidelines that support pharmacovigilance activities. ICH E2A covers Clinical safety data management. ICH E2B covers Data elements for transmission of individual case safety reports. ICH E2C covers Periodic safety update reports. ICH E2D covers Post approval safety data management. ICH E2E covers Pharmacovigilance planning.

Summary of Key ICH Guidelines:

Audit Types We Provide

Pharmacovigilance System Audits

We audit the overall pharmacovigilance system to verify that it meets regulatory requirements. This includes quality system for pharmacovigilance, organizational structure and responsibilities, personnel qualifications and training, standard operating procedures, documentation and record keeping, and compliance monitoring and CAPA.

Summary of Pharmacovigilance System Audits:

Pharmacovigilance System Master File Audits

We audit the Pharmacovigilance System Master File to verify that it is complete and current. This includes PSMF content and maintenance, annexes and supporting documents, change control and version management, and availability to authorities upon request.

Summary of Pharmacovigilance System Master File Audits:

Individual Case Safety Report Audits

We audit the processing and reporting of individual case safety reports. This includes case intake and data entry, case processing and medical review, coding and MedDRA terminology, follow up procedures, submission timelines and compliance, and electronic submission gateway compliance.

Summary of Individual Case Safety Report Audits:

Signal Detection and Management Audits

We audit signal detection and management processes to verify that safety signals are identified and managed appropriately. This includes signal detection methodologies, signal validation and prioritization, signal assessment and evaluation, signal management documentation, and communication of safety signals.

Summary of Signal Detection and Management Audits:

Risk Management Plan Audits

We audit risk management plans to verify that they meet regulatory requirements. This includes RMP content and updates, safety specifications, pharmacovigilance plans, risk minimization measures, and effectiveness evaluation.

Summary of Risk Management Plan Audits:

Periodic Safety Report Audits

We audit periodic safety reports to verify that they are complete and submitted on time. This includes PSUR/PBRER content and format, data analysis and benefit risk assessment, submission timelines, and regulatory authority responses.

Summary of Periodic Safety Report Audits:

Post Authorization Safety Study Audits

We audit post authorization safety studies to verify that they are conducted according to protocol and regulatory requirements. This includes PASS protocol and design, study conduct and monitoring, data analysis and reporting, and publication and communication.

Summary of Post Authorization Safety Study Audits:

Vendor and Service Provider Audits

We audit pharmacovigilance service providers to verify that they meet regulatory requirements. This includes PV service provider qualification, quality agreements and responsibilities, subcontractor management, and oversight and performance monitoring.

Summary of Vendor and Service Provider Audits:

Signal Detection Technology Audits

We audit the technology platforms used for signal detection and safety data management. This includes safety database validation, signal detection software validation, data mining methodologies, and access controls and audit trails.

Summary of Signal Detection Technology Audits:

Who We Work With and Our Partners

Clients We Serve

We serve marketing authorization holders, pharmaceutical companies, biotechnology companies, pharmacovigilance service providers, contract research organizations, medical device companies, vaccines manufacturers, and generic drug companies.

Summary of Clients We Serve:

Our Partners

We collaborate with pharmacovigilance software vendors, MedDRA and coding services, training providers, regulatory consultants, translation services, and medical writing services.

Summary of Our Partners:

Our GVP Audit Process

Phase Activities Output
Planning Scope, PV system review Audit plan
Document review SOPs, PSMF, procedures Pre audit analysis
On site Interviews, system review Working notes
Case review ICSR sampling, data verification Findings
Close out Classification and CAPA discussion Draft findings
Report Final report with prioritized actions Audit report
Follow up CAPA verification and closure Closure letter

Summary of GVP Audit Process:

Why Choose GxP Cellators for GVP Auditing

Summary of Why Choose GxP Cellators:

Contact Us for GVP Auditing Support

If you need to audit your pharmacovigilance system, assess signal detection, or prepare for an inspection, our GVP auditing team can help. Contact us to discuss your safety data and compliance needs.

    You cannot copy content of this page

    Verified by MonsterInsights